Abbott
Executive Summary
Filed NDA for the oral quinolone temafloxacin Nov. 30. Abbott is seeking a wide range of treatment indications, such as urinary tract and lower respiratory tract infections, including pneumonia and bronchitis; prostatitis; sexually transmitted diseases, including gonorrhea; and skin and skin structure infections.